Cbl-b-IN-5

• UNSPSC Description:

  Cbl-b-IN-5 (compound 6) is a Cbl-b inhibitor (IC50=3-10 µM). Cbl-b-IN-5 has the potential to be used in the study of cancer and related diseases amenable to immune system modulation[1].

• Target Antigen:

  E1/E2/E3 Enzyme

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/cbl-b-in-5.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC(C1=CC(NC(C2=NC=CC=C2)=O)=CC=C1)SC3=NN=CN3C

• Molecular Weight:

  339.41

• References & Citations:

  [1]Paul A. Barsanti, et al. Inhibitors of cbl-b and methods of use thereof. Patent WO2019148005A1.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2368835-59-8